Journey Medical Corporation (DERM)
USD 6.04
(-0.41%)
USD 6.04
(-0.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 54.59 Million USD | -26.93% |
| 2022 | 70.41 Million USD | 24.86% |
| 2021 | 56.39 Million USD | 155.32% |
| 2020 | 22.08 Million USD | 15.45% |
| 2019 | 19.13 Million USD | -92.5% |
| 2018 | 255.14 Million USD | -16.31% |
| 2017 | 304.86 Million USD | 169.3% |
| 2016 | 113.2 Million USD | 30.02% |
| 2015 | 87.07 Million USD | 123.27% |
| 2014 | 38.99 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.24 Million USD | -31.05% |
| 2024 Q1 | 16.3 Million USD | 43.7% |
| 2023 FY | 51.45 Million USD | -26.93% |
| 2023 Q3 | 10.86 Million USD | -21.92% |
| 2023 Q4 | 11.34 Million USD | 4.43% |
| 2023 Q1 | 15.32 Million USD | -16.0% |
| 2023 Q2 | 13.91 Million USD | -9.2% |
| 2022 Q2 | 17.8 Million USD | 11.38% |
| 2022 FY | 70.41 Million USD | 24.86% |
| 2022 Q1 | 15.98 Million USD | -6.26% |
| 2022 Q4 | 18.24 Million USD | -0.78% |
| 2022 Q3 | 18.38 Million USD | 3.3% |
| 2021 Q2 | 21.56 Million USD | 246.4% |
| 2021 Q3 | 11.54 Million USD | -46.45% |
| 2021 Q4 | 17.04 Million USD | 47.62% |
| 2021 FY | 56.39 Million USD | 155.32% |
| 2021 Q1 | 6.22 Million USD | 7.05% |
| 2020 Q3 | 5.82 Million USD | 22.66% |
| 2020 FY | 22.08 Million USD | 15.45% |
| 2020 Q2 | 4.75 Million USD | -8.97% |
| 2020 Q4 | 5.81 Million USD | -0.22% |
| 2020 Q1 | 5.22 Million USD | 0.0% |
| 2019 Q1 | 64.24 Million USD | -10.52% |
| 2019 FY | 19.13 Million USD | -92.5% |
| 2019 Q3 | 64.77 Million USD | -20.63% |
| 2019 Q2 | 81.61 Million USD | 27.03% |
| 2018 Q2 | 60.31 Million USD | 5.4% |
| 2018 Q3 | 65.8 Million USD | 9.1% |
| 2018 Q4 | 71.8 Million USD | 9.12% |
| 2018 FY | 255.14 Million USD | -16.31% |
| 2018 Q1 | 57.22 Million USD | 4.01% |
| 2017 Q1 | 31.18 Million USD | 2.74% |
| 2017 FY | 304.86 Million USD | 169.3% |
| 2017 Q4 | 55.01 Million USD | -69.28% |
| 2017 Q3 | 179.09 Million USD | 352.67% |
| 2017 Q2 | 39.56 Million USD | 26.87% |
| 2016 Q4 | 30.35 Million USD | 16.47% |
| 2016 Q3 | 26.06 Million USD | -7.06% |
| 2016 FY | 113.2 Million USD | 30.02% |
| 2016 Q2 | 28.04 Million USD | -2.48% |
| 2016 Q1 | 28.75 Million USD | -9.56% |
| 2015 Q1 | 14.23 Million USD | 1.08% |
| 2015 Q2 | 17.34 Million USD | 21.84% |
| 2015 Q3 | 23.57 Million USD | 35.93% |
| 2015 FY | 87.07 Million USD | 123.27% |
| 2015 Q4 | 31.79 Million USD | 34.87% |
| 2014 Q4 | 14.08 Million USD | 0.0% |
| 2014 FY | 38.99 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -561.515% |
| Alpha Teknova, Inc. | 45.85 Million USD | -19.048% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 72.144% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -21.715% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 65.709% |
| Cosmos Health Inc. | 26.18 Million USD | -108.527% |
| Embecta Corp. | 528.4 Million USD | 89.668% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 79.921% |
| Dynavax Technologies Corporation | 219.14 Million USD | 75.088% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 90.747% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 83.273% |
| PainReform Ltd. | 9.58 Million USD | -469.637% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -315.971% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -315.971% |
| SCYNEXIS, Inc. | 51.84 Million USD | -5.296% |
| Safety Shot Inc | 12.1 Million USD | -350.829% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1678.777% |
| Procaps Group, S.A. | 199.47 Million USD | 72.631% |
| Theratechnologies Inc. | 72.75 Million USD | 24.963% |
| Harrow Health, Inc. | 89.97 Million USD | 39.322% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -477.959% |
| Biofrontera Inc. | 39.95 Million USD | -36.625% |
| DURECT Corporation | 43.71 Million USD | -24.886% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 89.68% |
| Cronos Group Inc. | 96.7 Million USD | 43.548% |
| OptiNose, Inc. | 85.1 Million USD | 35.849% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 76.481% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -39.438% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 671.007% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 82.621% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -461.041% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -26.843% |
| Radius Health, Inc. | 265.92 Million USD | 79.47% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -294.411% |
| ProPhase Labs, Inc. | 37.85 Million USD | -44.23% |
| Phibro Animal Health Corporation | 260.29 Million USD | 79.026% |
| Procaps Group S.A. | 187.24 Million USD | 70.844% |
| Alvotech | 285.43 Million USD | 80.874% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -455.664% |
| Viatris Inc. | 5.96 Billion USD | 99.085% |
| Rockwell Medical, Inc. | 15.37 Million USD | -255.106% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 8.767% |
| SIGA Technologies, Inc. | 22.04 Million USD | -147.67% |
| Tilray Brands, Inc. | 251.35 Million USD | 78.28% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -11.33% |
| Shineco, Inc. | 17.94 Million USD | -204.178% |
| PetIQ, Inc. | 192.72 Million USD | 71.673% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1267.881% |
| Incannex Healthcare Limited | 30.05 Million USD | -81.659% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.58% |
| Alimera Sciences, Inc. | 62.64 Million USD | 12.846% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -7059.944% |
| Assertio Holdings, Inc. | 368.58 Million USD | 85.188% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -827.591% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -206.561% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -157.896% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -159.451% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 66.906% |
| Hempacco Co., Inc. | 7.59 Million USD | -618.678% |
| Talphera, Inc. | 11.99 Million USD | -355.178% |
| Alvotech | 285.43 Million USD | 80.874% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 61.202% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 84.171% |
| Currenc Group, Inc. | 24 Million USD | -127.455% |
| Kamada Ltd. | 45.42 Million USD | -20.182% |
| Indivior PLC | 911 Million USD | 94.007% |
| Evoke Pharma, Inc. | 12.4 Million USD | -339.932% |
| Flora Growth Corp. | 10.57 Million USD | -416.06% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -159.451% |
| Evolus, Inc. | 189.75 Million USD | 71.23% |
| HUTCHMED (China) Limited | 436.23 Million USD | 87.485% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 64.58% |
| Akanda Corp. | 3.48 Million USD | -1467.213% |